New AI Model Speeding Up Drug Discovery Research

Liquid AI and Insilico Medicine announced a partnership to launch a new foundation model for pharmaceutical research ^[1]. The model, known as LFM2-2.6B-MMAI, features 2.6 billion parameters ^[2]. It aims to accelerate the end-to-end drug discovery process while maintaining performance comparable to much larger AI systems ^[3]. The system is designed to run on private infrastructure, addressing data privacy concerns in the biotech industry ^[1]. Researchers can use the lightweight model for various tasks, including molecular modeling and target identification ^[2]. This development marks a shift toward more efficient AI tools for global drug development teams ^[3].